NCT04867551 is a Phase 2 clinical trial of KDT-3594 in Parkinson Disease, sponsored by Kissei Pharmaceutical Co., Ltd..

Who is sponsoring NCT04867551?

NCT04867551 is sponsored by Kissei Pharmaceutical Co., Ltd..

What drugs are being tested in NCT04867551?

Interventions in NCT04867551: KDT-3594.

What condition does NCT04867551 study?

NCT04867551 studies Parkinson Disease.

Is NCT04867551 still recruiting?

NCT04867551 is currently completed. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT04867551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

Completed Phase 2 Last updated 11 May 2022

What this trial tests

Phase 2 trial testing KDT-3594 in Parkinson Disease in 7 participants. Completed in 6 September 2021.

Timeline

15 May 2021

Primary endpoint
6 September 2021

6 September 2021

Quick facts

Lead sponsor	Kissei Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	15 May 2021
Primary completion	6 September 2021
Estimated completion	6 September 2021
Sites	1 location across Japan

Drugs / interventions tested

KDT-3594 — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Kissei Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 20 to 79, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.
Dong-Chen X, Yong C, Yang X, Chen-Yu S, et al · · 2023 · cited 258× · PMID 36810524 · DOI 10.1038/s41392-023-01353-3

Verify or expand the search:

Other trials of KDT-3594

Trials testing the same drug.

NCT03845387 — A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. · Phase 2 · completed
NCT03068481 — Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease · Phase 1 · completed

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Kissei Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06757257 — Special Drug Use-results Survey for Long-term Use (Fostamatinib) · recruiting
NCT05831670 — An Early Phase 2 Clinical Study of KSP-0243 · Phase 2 · completed
NCT05445167 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain · Phase 3 · completed
NCT05440383 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia · Phase 3 · completed
NCT06758271 — Special Drug Use-results Survey for Long-term Use（Avacopan） · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04867551 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kissei Pharmaceutical Co., Ltd.
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04867551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing